Travis Tingey
ePharma IMPACT brings together influential players across the digital marketing spectrum to reveal next generation omni-channel strategies for stronger patient and HCP relationships, and greater influence over impactful marketing strategy. ICON's Travis Tingey attended the recent conference and shares his thoughts on some notable trends and themes.
Silicon Valley Is Coming to Pharma
Across all industries, customers have begun to disregard corporate brand identity being key in decision-making—it matters less how a company talks about the product and more what peers think about the product. Driven by our constant connection to social networks, today’s consumers rely on word-of-mouth recommendations for products. As we’re increasingly engaged with platforms like Facebook, Twitter, and Instagram, “influencer marketing” has taken hold. Now the value of the product is equated to the influencer’s authenticity. “Lifestyle marketing” has emerged, where the products we buy must also represent a way of life or take a stance on social issues that will resonate with consumers.
One interview at ePharma exemplified this shift taking place within the pharmaceutical industry. Former Google employee Steven Gutentag is the cofounder of Keeps, a business focused on branding an entire disease state of men’s hair loss. This business model follows other successful internet-based businesses that are “disrupting” the traditional brick-and-mortar approach. With the platform, doctors connect with patients through telemedicine for prescriptions. Generic forms of Rogaine and Propecia are supplied directly to consumers. Keeps’ lifestyle brand identity permeates the platform, positioning it as the one-stop solution for hair-loss treatments—all of which are supported by digital ad campaigns. By focusing on the disease state, the brand represents the solution for patients and not the drugs themselves.
From consulting, to prescribing, to packaging, to distributing, Keeps controls the supply chain with vertical integration in order to drive costs down. Doing so has allowed Keeps to compete directly with doctor visits and pharmacy prescription fills, bypassing payers completely. While the current business is selling generics, he believes this model can be applied to other drugs. Gutentag’s company is currently working on another brand dedicated to migraine treatments that is leveraging the same business model.
Artificial Intelligence Within Healthcare
In a talk, David Gome provided examples of how artificial intelligence (AI) is currently being leveraged and opportunities within the life sciences industry. Deep-learning algorithms created for image recognition have surpassed human accuracy since 2015. In one example, one type of AI was trained to accurately predict the cancer stage of mesothelioma as well as probability of the types of genetic mutations based on diagnostic image alone. The technology is already out there, and we will soon see how AI will change the approach in diagnosis and treatment of patients.
AI systems require massive amounts of data to train machine-learning algorithms. The mass adoption of customer relationship managements (CRMs), such as Veeva and SalesForce, by manufacturers is a sign that they are already collecting big data, but their challenge is still codifying their data and building infrastructure to make sense of it. While agencies are unlikely to provide that level of service for their clients, social monitoring platforms that use AI are already available and can be leveraged to generate useful insights and targeted marketing for manufacturers.
Gome pointed to another study that showed the importance of social connections and thought leadership among physicians. The study demonstrated that a single key opinion leader (KOL) leading a meeting netted a prescription growth of only 7%. However, a KOL speaking with more than 1 colleague attending had a net prescription growth of 89%. The role of the social influencer is critical even within healthcare.
Social monitoring platforms have great potential to aid in research around where public dialog is occurring and which patients, physicians, and organisations have the greatest social reach. This could be a new opportunity for to provide more targeted campaigns for both patients and HCPs.
Learn more
To learn more, contact our Commercialisation and Outcomes Services team.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
AI at ICON
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel